[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"apathy-in-dementia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:apathy-in-dementia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,56,82,106,137,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100053800","the-volunteering-in-place-program-for-apathetic-assisted-living-residents-with-adrd-100053800",false,"NCT06735950","The Volunteering-in-Place Program for Apathetic Assisted Living Residents With ADRD","Inclusion Criteria:\n\n* age 55 years or older;\n* English speaking;\n* live in the included AL community\n* have mild to moderate cognitive impairment based on a SLUMS score of 26 or below and the ability to follow a one-step command.\n* have apathy based on a \"yes\" answer to at least 2 questions on the apathy subscale of the Neuropsychiatric Inventory (NPI) completed by a family or staff member who has had close contact with the resident in the past month;\n* have an anticipated length of stay of 12 months.\n\nExclusion Criteria:\n\n\\- refusal to assent","ALL","55 Years",{"count":18,"type":19},200,"ESTIMATED","INTERVENTIONAL",[22],"NA","This is a research study to test two different interventions to decrease apathy in assisted living residents with some memory issues. Apathy makes older adults not feel like doing much activity. This study is completely voluntary and will not affect the care you receive at your assisted living community.\n\nThe two possible interventions are 1) participation in a volunteering opportunity within the assisted living community OR 2) participation in a guided current events group within the assisted living community. These activities would be in addition to any other regular activities you participate in within the assisted living community. Both activities would take place three days per week for approximately 30 minutes. You would be randomly assigned (like a coin flip) to which intervention you would do. You do not get to choose. You would participate in the activity for a total of 6 months.\n\nIn addition to participating in the intervention (either volunteering or current events), you will be asked to answer some questions about your memory, level of activity, mood, confidence in your ability to do a volunteer job, and feelings of usefulness. You will answer these questions at baseline (before the activity begins, at 3 months after doing the intervention activity, and aging at 6 months after starting the interventions activity. You will also be asked to wear a MotionWatch for 5 days at each time point (baseline, 3months and 6 months). A motion watch measures your level of activity. It feels like wearing a regular watch. You will be in the study for 6 months total.\n\nRisks to participating in this study are minimal and include privacy (other people may find out you are in the study), confidentiality of the data collected if someone other than study staff accesses your records, fatigue with answering the questionnaires, and some mild discomfort with wearing the MotionWatch. This is also a minor risk that you could fall or otherwise harm yourself getting to or participating in your intervention activity.\n\nThe benefit of participating in this study include possible enjoyment of participating in the intervention activity.",[25],"Apathy in Dementia",[27,28,29,30],"apathy","assisted living","dementia","volunteering","NOT_YET_RECRUITING","2026-07-09",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":19},"2026-07-30",{"date":39,"type":19},"2027-08-31",{"name":41,"class":42},"University of Maryland, Baltimore","OTHER",{"id":44,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":46,"briefSummary":23,"conditions":47,"keywords":48,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":53,"leadSponsor":55,"locationsCount":4},"100572644",{"count":18,"type":19},[22],[25],[27,28,29,30],"2026-07-01",{"date":51,"type":35},"2026-07-02",{"date":37,"type":19},{"date":54,"type":19},"2027-08",{"name":41,"class":42},{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":15,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":20,"phases":67,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":79,"locationsCount":81},"100628950","sensrem---sensoriality-and-multi-sensory-emotional-reminiscences-a-pilot-study-100628950","NCT07468305","SENS'REM - SENSoriality and Multi-Sensory Emotional Reminiscences: a Pilot Study","SENS'REM - SENSoriality and Multi-Sensory Emotional Reminiscences: Feasibility of Multi-Sensory Reminiscence in Virtual Reality on Apathy in Elderly People With Cognitive Disorders in Nursing Homes and Long-Term Care Units","SENS'REM","Inclusion Criteria:\n\n* Men or women aged 70 years or older\n* Living in a nursing home (EHPAD) or long-term care unit (USLD) for at least 3 months\n* Sufficient French language ability to understand the study procedures\n* Presence of apathy confirmed by a positive score on the Apathy Inventory\n* Moderate cognitive impairment documented by a Montreal Cognitive Assessment (MoCA) score between 10 and 17\n* Affiliated with a social security or health insurance system\n* Medical approval for virtual reality exposure (no contraindication)\n* Ability to provide informed consent, or consent provided by a legal representative or trusted person when applicable\n\nExclusion Criteria:\n\n* \"Diagnosed psychiatric disorder according to DSM-5 criteria (e.g., schizophrenia, bipolar disorder)\n* Severe or acute behavioral disturbances incompatible with study participation\n* Neurological comorbidities incompatible with virtual reality use (e.g., Lewy body disease, history of epilepsy)\n* Severe sensory impairment (vision, hearing, or olfaction) preventing participation\n* Known susceptibility to cybersickness based on the CyberSickness in Virtual Reality Questionnaire (CSQ-VR)\n* Presence of a cardiac pacemaker incompatible with virtual reality headset use\n* Withdrawal of informed consent at any time during the study\"","65 Years",{"count":66,"type":19},10,[22],"SENS'REM is a pilot feasibility study evaluating a new non-drug therapeutic program based on multisensory reminiscence using immersive virtual reality in older adults living in nursing homes or long-term care units who present cognitive impairment and apathy.\n\nApathy is a frequent symptom in people with neurocognitive disorders. It is characterized by a loss of motivation, reduced interest in activities, and decreased emotional engagement. Apathy strongly affects quality of life, social interactions, and participation in care, and current drug treatments have limited effectiveness. For this reason, non-pharmacological approaches are increasingly recommended.\n\nThe SENS'REM program combines virtual reality with personalized multisensory stimulation (visual, auditory, olfactory and gustatory) to help participants relive meaningful autobiographical memories in an immersive and emotionally engaging environment. Each participant receives one session per week for six weeks. The content of the sessions is adapted to the individual life history of each participant.\n\nThe primary objective of this study is to evaluate the feasibility of implementing this program in institutional settings, including recruitment, organization, technical aspects, and participant adherence. Secondary objectives include evaluating changes in apathy, quality of life, cognitive functioning, social engagement, participant satisfaction, and the tolerance of the intervention.\n\nThe main hypothesis of the study is that a personalized multisensory virtual reality reminiscence program is feasible in nursing home and long-term care settings and may contribute to a reduction in apathy and an improvement in engagement and well-being among older adults with cognitive impairment.\n\nThis pilot study will provide essential preliminary data to optimize the intervention and prepare a future larger comparative clinical trial.",[70,25],"Apathy",[72,27,29],"Neurocognitive disorders","2026-05-21",{"date":75,"type":35},"2026-05-26",{"date":77,"type":19},"2026-09",{"date":54,"type":19},{"name":80,"class":42},"Centre Hospitalier Universitaire de Nice",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":15,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":20,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":81},"100624036","robotic-technologies-for-apathy-in-dementia-a-randomised-controlled-trial-raphael-100624036","NCT07404410","Robotic Technologies for APATHy in Dementia: a Randomised Controlled Trial (RAPHAel)","RAPHAel","Inclusion Criteria:\n\n* Age 40 years or older\n* Clinical diagnosis of a neurocognitive disorder, including: Mild cognitive impairment (MCI) or mild behavioral impairment (MBI), or Major neurocognitive disorder (dementia), due to Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, or other neurodegenerative diseases.\n* Presence of clinically relevant apathy, defined as a score greater than 2 on the apathy domain (G) of the Neuropsychiatric Inventory (NPI).\n* Preserved ability to understand and produce spoken and written language sufficient to participate in the intervention and assessments.\n* Absence of clinically significant agitation or aggressiveness, defined as a score lower than 2 on the agitation\u002Faggression domain (C) of the NPI.\n* Adequate educational and occupational history sufficient to exclude intellectual disability.\n* Availability of a study partner (family member, friend, or caregiver) who: Knows the participant well, Has contact with the participant for at least 10 hours per week, Is able to complete questionnaires about the participant, Is able to read, understand, and speak Italian, and Provides independent informed consent for participation.\n* Ability and willingness of the participant (and study partner, when applicable) to provide informed consent.\n\nExclusion criteria:\n\n* Refusal or withdrawal of informed consent by the participant or the study partner.\n* History or current evidence of neurological conditions other than the target neurodegenerative diseases that may affect cognitive function (e.g., major stroke, brain tumor, normal pressure hydrocephalus, traumatic brain injury).\n* History or current diagnosis of major psychiatric disorders that could interfere with study participation or assessments.\n* Presence of medical conditions that may significantly affect cognitive function (e.g., severe renal or hepatic failure, untreated obstructive sleep apnea, hypothyroidism, vitamin B12 deficiency).\n* Clinically significant agitation or aggressiveness, defined as a score of 2 or higher on the agitation\u002Faggression domain (C) of the Neuropsychiatric Inventory (NPI).\n* Inability to understand or communicate in Italian sufficient to complete study procedures.\n* Absence of an eligible study partner or withdrawal of consent by the study partner.","40 Years",{"count":91,"type":19},75,[22],"The goal of this trial is to learn whether home-based robotic interventions can reduce apathy in people with cognitive decline. Apathy means reduced motivation, interest, or initiative in daily life. It is a common and distressing symptom in people with mild cognitive impairment (MCI) or dementia and can strongly affect both participants and their caregivers.\n\nThis study will compare two different robotic interventions with standard occupational therapy. Researchers want to understand if these new technologies can help people become more engaged, motivated, and involved in everyday activities, and whether they also reduce stress and improve quality of life for caregivers.\n\nThe main questions this study aims to answer are:\n\n* Do robotic interventions reduce apathy more than standard occupational therapy?\n* Are these robotic interventions easy to use and acceptable for people with cognitive impairment?\n* Do these interventions reduce caregiver stress and improve caregiver quality of life?\n\nParticipants will be adults over 40 years of age with a diagnosis of mild cognitive impairment or dementia caused by a neurodegenerative disease, such as Alzheimer's disease, frontotemporal dementia, or dementia with Lewy bodies. All participants must show clinically relevant apathy and have a family member or caregiver who can support them during the study and answer questionnaires.\n\nParticipants will be randomly assigned to one of three groups:\n\n* A telepresence robot group, where participants interact at home with a therapist through a remotely controlled robot that delivers personalized cognitive stimulation.\n* A social robot group, where participants interact at home with a humanoid robot that holds personalized conversations on topics of interest.\n* A control group receiving home-based occupational therapy, which is the current standard care for behavioral symptoms.\n\nEach intervention lasts six weeks and takes place in the participant's home. The robotic interventions are designed to fit into daily routines and can be adapted to the participant's abilities and preferences. Occupational therapy sessions focus on meaningful activities, environmental adaptations, and caregiver support.\n\nParticipants will complete assessments at three time points: before the intervention, at the end of the six-week intervention, and eight weeks after the intervention ends. These assessments include interviews, questionnaires, and simple tasks to measure apathy, emotional responses, social interaction, and quality of life. Caregivers will also complete questionnaires about stress and daily burden.\n\nResearchers will also collect information about how often and how participants interact with the robots, such as how long conversations last and how engaged participants appear. These data will help researchers understand how robotic interactions relate to changes in apathy and behavior.\n\nThis study aims to provide evidence on whether robotic technologies can be safely and effectively used at home to support people with cognitive impairment and apathy. The results may help develop new non-drug treatments and improve care options for people living with dementia and their caregivers.",[70,25],[29,27,96],"robotics","RECRUITING","2026-04-28",{"date":100,"type":35},"2026-05-05",{"date":98,"type":35},{"date":103,"type":19},"2026-11-30",{"name":105,"class":42},"Giovanna Zamboni",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":20,"phases":115,"briefSummary":116,"conditions":117,"keywords":123,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100482374","rtms-for-apathy-clinical-trial-100482374","NCT05561205","rTMS for Apathy Clinical Trial","Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)","REACT","Inclusion Criteria:\n\n* mild or major neurocognitive disorder OR mild behavioural impairment\n* Apathy for at least 4 weeks\n* Stable dose of medication (\\>4 weeks) that may affect cognition or behaviour\n* Care partner who spends at least 10 hours a week with the subject\n\nExclusion Criteria:\n\n* Current major depressive episode\n* Agitation, delusions, hallucination\n* Medical contraindications to rTMS\n* Currently taking an amphetamine product\n* Central nervous system abnormalities, Tourette's syndrome, or motor tics\n* Current participation in another clinical trial",{"count":66,"type":19},[22],"Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.",[118,25,119,120,121,122],"Alzheimer Disease","Dementia","Mild Behavioural Impairment","Mild Cognitive Impairment","Neurocognitive Disorders",[70,124,125,126],"Alzheimer's disease","Neurocognitive disorder","Mild behavioural impairment","2026-04-10",{"date":129,"type":35},"2026-04-13",{"date":131,"type":35},"2023-02-09",{"date":133,"type":19},"2026-12-01",{"name":135,"class":42},"Sunnybrook Health Sciences Centre",1,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":15,"minAge":144,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":148,"conditions":149,"keywords":153,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":167},"100611163","effects-of-personalized-digital-reminiscence-therapy-on-patients-with-neurocognitive-disorders-100611163","NCT07237009","Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders","Effects of Personalized Reminiscence Sessions Delivered by a Digital Conversational Agent to Patients With Neurocognitive Disorders","Inclusion Criteria:\n\n* Men and women over 60 years of age.\n* DSM-5 diagnosis: Early stage of major neurocognitive disorders or MCI (Mild Cognitive Impairment) including all underlying causes.\n* Have a Mini-Mental State Exam score of 21 ≤ MMSE ≤ 28.\n* Presence of mild or moderate depression, or presence of mild or moderate apathy, or presence of both\n* Displays the necessary physical and cognitive abilities, without major limitations compromising interaction with the digital tool.\n* Having voluntarily and informedly agreed to participate in the study (signed written consent).\n* Subject's ability to hear and see the digital tool's stimuli (tests integrated into the tool).\n* Patients with access to an Apple device (smartphone or tablet), either personal or provided by the sponsor, running iOS version 16 or higher, with internet access.\n* Patient has at least one close referent who declares their wish to contribute to the collection of biographical information via the digital messaging group.\n* Subjects covered by a social security scheme.\n\nExclusion Criteria:\n\n* Patients with moderate or severe dementia (MMSE score ≤ 20) because implicit memory recall is less effective in moderate or severe stages for people with PWD.\n* Presence of major psychiatric disorders (e.g., schizophrenia, severe major depressive episode, bipolar disorder).\n* Major hearing or visual impairments.\n* History of premorbid intellectual disability.\n* Patients under guardianship, conservatorship, or legal protection.\n* Patients who have already used the Lilia app\n* Participating simultaneously in another study involving human subjects, a clinical investigation, or a therapeutic trial for the entire duration of the study.\n* Patients who have received a new treatment related to neurocognitive disorders (medication) during the 3 months prior to the inclusion visit.","60 Years",{"count":146,"type":19},80,"OBSERVATIONAL","This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such as apathy and depression.\n\nThe researchers therefore seek to observe whether this daily use can improve certain aspects of well-being, such as motivation, mood, sleep quality, quality of life, and engagement with the tool.\n\nThe study also aims to assess whether simple reminders delivered via the application are sufficient to encourage regular use without external assistance.\n\nParticipants will:\n\n* Use the reminiscence app for 25 days for 10-15 minutes.\n* Have a primary caregiver help personalize the app by sharing family memories, other relatives may optionally contribute in a private group.\n* Complete brief questionnaires at the start and during follow-up routine visits (for example, apathy and depression scales, sleep, and quality of life).",[150,151,152,70,25],"Neurocognitive Disorders, Mild","Cognitive Impairment, Mild","Depression Mild",[121,119,70,154,155,156],"Mild Depression","Digital Reminiscence therapy","personalized Reminiscence therapy","2026-03-06",{"date":159,"type":35},"2026-03-09",{"date":161,"type":35},"2025-10-14",{"date":163,"type":19},"2026-12",{"name":165,"class":166},"KompanionCare SAS","INDUSTRY",5,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":20,"phases":178,"briefSummary":180,"conditions":181,"keywords":185,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":136},"100614449","phase-2-combined-brain-stimulation-and-methylphenidate-treatment-for-apathy-in-dementia-100614449","NCT07279740","Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia","Methylphenidate Primed iTBS for Apathy in Neurocognitive Disorders","PRIME","Inclusion Criteria:\n\n* Alzheimer's disease or mixed Alzheimer's disease and vascular disease\n* MMSE score 10-28 inclusive\n* Clinically significant apathy\n* Stable dose of psychotropic medication\n* Care partner must spend at least 10hrs\u002Fweek with the participant\n\nExclusion Criteria:\n\n* Major Depressive Episode\n* Clinically significant agitation, delusions, hallucinations\n* Currently talking a dopaminergic agent other than methylphenidate\n* Failure to clear the TMS adult safety scale (e.g. unapproved pacemakers, metallic implants, history of epilepsy)\n* Central nervous system abnormalities (other than Alzheimer's disease) deemed clinically significant by study physician or seizures\n* Any condition that in the opinion of the study physician, makes it medically unsafe for the patient to enroll in the trial",{"count":177,"type":19},12,[179],"PHASE2","This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat apathy in individuals with Alzheimer's disease or mixed AD\u002Fvascular dementia",[182,183,184,118,70,25],"Alzheimer s Disease","Alzheimer Dementia (AD)","Alzheimer Dementia",[27,29,124,186,187,188,189,190],"methylphenidate","rTMS","iTBS","repetitive transcranial magnetic stimulation","intermittent theta burst stimulation","2025-12-11",{"date":193,"type":35},"2025-12-12",{"date":195,"type":19},"2026-01",{"date":197,"type":19},"2027-10-01",{"name":135,"class":42}]